We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Arrayjet and JPT Peptide Technologies Finalise Strategic Deal

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Arrayjet and JPT Peptide Technologies Finalise Strategic Deal"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Arrayjet Ltd are pleased to announce today the installation of a customised version of an Ultra Marathon microarrayer, one of the largest capacity microarrayers currently available at JPT Peptide Technologies GmbH.

The Ultra Marathon is Arrayjet's top-of-the-range inkjet microarrayer, designed for commercial large scale manufacturing, capable of printing up to 1,000 slides fully automated in a single run. The Ultra Marathon utilises Arrayjet's unique non-contact inkjet technology which delivers unrivalled speed and precision to produce high quality, reproducible microarrays faster than any other technology.

Dr Iain McWilliam, CEO of Arrayjet commented, ''We are delighted to have secured this deal with JPT Peptide Technologies. JPT is the world leader in peptide microarray technologies for a large variety of applications and we are very pleased they have chosen an Arrayjet microarrayer to bring their high-content peptide microarray manufacturing to the next level. We hope this is the beginning of a long-term collaborative relationship and I'm looking forward to seeing this cooperation generate significant growth for both companies''.

 Arrayjet's Commercial Director, Claire Jenkins said, ''It's an exciting time at Arrayjet. We launched our service business last year to offer a wider range of solutions to our customers. This deal with JPT helps demonstrate that to be a real solutions provider you need an offering to meet all individual customer requirements. I'm thrilled that the Ultra Marathon has the capacity, speed and reproducibility to meet the specific needs of JPT and I look forward to seeing the Ultra Marathon deliver their results moving forward''.

Dr Holger Wenschuh, CEO at JPT added, “We are very excited about the growing appreciation of our PepStarTM peptide microarray platform by the vaccine and immunotherapy community as well as the diagnostic arena. To comply with large immune monitoring and biomarker discovery projects thousands of high content peptide microarrays need to be assembled in our clean-room facilities with the highest reproducibility and accuracy. We are glad to have found a dedicated partner that accepted the specific challenges of our regulated production environment and developed an instrument tailored to our needs.”